Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. 1985

T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols

UI MeSH Term Description Entries
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008717 Methionine Sulfoximine Sulfoximine, Methionine
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females

Related Publications

T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
May 1988, Cancer research,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
January 1987, Biochemical pharmacology,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
November 1984, Cancer research,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
May 1993, Cancer research,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
June 1994, Nihon Sanka Fujinka Gakkai zasshi,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
April 1989, Journal of the National Cancer Institute,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
January 1995, Cancer chemotherapy and pharmacology,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
January 1994, Cancer chemotherapy and pharmacology,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
November 1988, Biochemical pharmacology,
T C Hamilton, and M A Winker, and K G Louie, and G Batist, and B C Behrens, and T Tsuruo, and K R Grotzinger, and W M McKoy, and R C Young, and R F Ozols
August 1995, International journal of oncology,
Copied contents to your clipboard!